Results 11 to 20 of about 2,019 (146)

Impurity study of tecovirimat

Heliyon
This article delineates the systematic identification, synthesis, and impurity control methods used during the manufacturing process development of tecovirimat, an antiviral drug that treats monkeypox.
Emmanuel Mintah Bonku, Hongjian Qin, Abdullajon Odilov, Safomuddin Abduahadi, Samuel Desta Guma, Feipu Yang, Xinglong Xing, Xukun Wang, Jingshan Shen   +8 more
doaj   +3 more sources

Eczema Monkeypoxicum Following Sexual Transmission Treated With Tecovirimat

JEADV Clinical Practice
Mpox is a zoonotic viral infection caused by monkeypox virus (MPXV) and risk factors for its dissemination include previous dermatoses such as atopic dermatitis [1].
Andrés Vidal González, Sergio López Alcázar, José Ángel Amat Sánchez, Francisco Vergara Barria, Rosa Feltes Ochoa, Elena Sendagorta Cudos, Pedro Herranz Pinto   +6 more
doaj   +2 more sources

Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox

BMJ Open, 2023
Introduction Monkeypox was originally endemic locally in West Africa; however, outbreaks in non-endemic countries have been recognised since May 2022.
Norio Ohmagari, Sho Saito, Shinya Tsuzuki, Tetsuya Suzuki, Shinobu Ashida, Mizue Takakusaki, Tomoki Yoshikawa, Masayuki Shimojima, Hideki Ebihara, Shinichiro Morioka   +9 more
doaj   +1 more source

Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.

PLoS Biology, 2023
Despite use of tecovirimat since the beginning of the 2022 outbreak, few data have been published on its antiviral effect in humans. We here predict tecovirimat efficacy using a unique set of data in nonhuman primates (NHPs) and humans.
Bach Tran Nguyen, Aurélien Marc, Clara Suñer, Michael Marks, Maria Ubals, Águeda Hernández-Rodríguez, María Ángeles Melendez, Movie Group, Dennis E Hruby, Andrew T Russo, France Mentré, Oriol Mitjà, Douglas W Grosenbach, Jérémie Guedj   +13 more
doaj   +1 more source

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Emerging Infectious Diseases, 2023
Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report
Caitlin A. Contag, Leah Mische, Isabel Fong, Abraar Karan, Akanksha Vaidya, David W. McCormick, William Bower, Jill K. Hacker, Kelly Johnson, Perla SanJuan, Linda Crebbin, Caroline Temmins, Harleen Sahni, Yael Bogler, Joseph D. Cooper, Supriya Narasimhan   +15 more
doaj   +1 more source

Navigating the expanded access investigational new drug protocol for tecovirimat: lessons learned from a public–private hospital partnership during the 2022 NYC mpox outbreak

Antimicrobial Stewardship & Healthcare Epidemiology, 2023
During the 2022 mpox outbreak, tecovirimat was accessed through an expanded access investigational new drug (EA-IND) protocol. We leveraged a unique public/private hospital partnership in New York City to create a novel infrastructure to navigate the EA ...
Ofole Mgbako, Justin Chan, Robert A. Pitts, Madeline A. DiLorenzo, Dorothy Knutsen, Dana Mazo   +5 more
doaj   +1 more source

A Global Health Alert on the Re-Emergence of Mpox a Viral Zoonotic Illness Its Prevention and Management: A Narrative Review. [PDF]

Health Sci Rep
ABSTRACT Background and Aims Monkeypox virus (MPXV) is gaining attention in the global health community due to its potential for human transmission and similarities to the well‐known smallpox virus. Mpox was first detected in the 1970s and mostly affects Central and West Africa.
Aqeel MB, Hanif A, Ahmad S, Shah FI, Javed B, Javed B, Iqbal S.   +6 more
europepmc   +2 more sources

Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus

Viruses, 2023
Monkeypox is a serious public health issue in tropical and subtropical areas. Antivirals that target monkeypox proteins might lead to more effective and efficient therapy. The F13 protein is essential for the growth and maturation of the monkeypox virus.
Yasir Ali, Hina Imtiaz, Muhammad Mutaal Tahir, Fouzia Gul, Umair Ali Khan Saddozai, Ashfaq ur Rehman, Zhi-Guang Ren, Saadullah Khattak, Xin-Ying Ji   +8 more
doaj   +1 more source

Tecovirimat for the Treatment of Mpox. [PDF]

N Engl J Med
Tecovirimat is approved for smallpox treatment under the Food and Drug Administration Animal Rule on the basis of efficacy in nonhuman primate models of mpox (previously known as monkeypox). However, the clinical efficacy of tecovirimat against human clade II mpox is unclear.In a phase 3, international, double-blind, randomized, placebo-controlled ...
Zucker J, Fischer WA, Zheng L, McCarthy C, Saha PT, Javan AC, Greninger A, Hamill MM, Leslie K, Brooks KM, Berardi J, Smith D, Hosey L, Aldrovandi G, Ferbas K, Day C, Bender Ignacio RA, Bolan R, Glesby MJ, Landovitz RJ, Luetkemeyer AF, Sierra Madero J, Gandhi RT, Nachman S, Eron J, Currier JS, Wilkin T, STOMP/A5418 Investigators.   +27 more
europepmc   +3 more sources

Trends of Pathogenicity and Potential Risk Evaluation of Central African Mpox Variant to Cause Global Public Health Emergency: A Cross-Sectional Analysis. [PDF]

Health Sci Rep
ABSTRACT Background With the re‐emergence of monkeypox (Mpox), it is vital for communities to assess and effectively respond to emerging outbreaks. This paper aims to review the potential of clade I Mpox to result in a widespread outbreak by assessing genetically enhanced virulence, transmission, and clinical manifestations.
Rahman MA, Kozlowich C, Katulka N, Thomas MR, Shanjana Y, Islam MR.   +5 more
europepmc   +2 more sources